Results 271 to 280 of about 655,147 (306)

Apixaban: an emerging oral factor Xa inhibitor

Journal of Thrombosis and Thrombolysis, 2009
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for the prevention and treatment of thromboembolic diseases. In comparison with current treatment standards for venous thromboembolism (VTE) prophylaxis, apixaban has shown decreased rates of clinically significant bleeding with mixed results in terms of non ...
Christopher, Roser-Jones, Richard C, Becker   +1 more
openaire   +2 more sources

Rivaroxaban, an oral direct factor Xa inhibitor

Expert Opinion on Investigational Drugs, 2008
Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists. Rivaroxaban is being investigated for the prevention and treatment of venous and arterial thrombosis. A broad search of Medline, clinicaltrials.gov and the annual proceedings of the American Society of Hematology and the
Jonathan P, Piccini, Manesh R, Patel, Kenneth W, Mahaffey, Keith A A, Fox, Robert M, Califf   +4 more
openaire   +2 more sources

Apixaban: an Oral Direct Factor-Xa Inhibitor

Advances in Therapy, 2012
Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable pharmacokinetic profile, multiple pathways of elimination, an improved bleeding profile relative to warfarin with a lack of other significant adverse events, and no need ...
David, Jiménez, Roger D, Yusen, Eduardo, Ramacciotti   +2 more
openaire   +2 more sources

1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa

Journal of Medicinal Chemistry, 2000
High-throughput screening of a combinatorial library of diamidophenols yielded lead compounds with the ability to inhibit human factor Xa (fXa) at micromolar concentrations (e.g. compound 4, fXa apparent K(ass) = 0.64 x 10(6) L/mol). SAR studies in this novel structural series of fXa inhibitors showed that the phenolic hydroxyl group was not essential ...
D K, Herron, T, Goodson, M R, Wiley, L C, Weir, J A, Kyle, Y K, Yee, A L, Tebbe, J M, Tinsley, D, Mendel, J J, Masters, J B, Franciskovich, J S, Sawyer, D W, Beight, A M, Ratz, G, Milot, S E, Hall, V J, Klimkowski, J H, Wikel, B J, Eastwood, R D, Towner, D S, Gifford-Moore, T J, Craft, G F, Smith   +22 more
openaire   +2 more sources

Isoxazolines and isoxazoles as factor Xa inhibitors

Bioorganic & Medicinal Chemistry Letters, 2000
3,4,5-Trisubstituted isoxazolines (2) and isoxazoles (3) were prepared and evaluated for their in vitro and in vivo antithrombotic efficacy. They were compared to 3,5,5-trisubstituted isoxazolines (1) for Factor Xa selectivity and potency. They were also compared in an arterio-venous (A-V) shunt model of thrombosis.
J R, Pruitt, D J, Pinto, M J, Estrella, L L, Bostrom, R M, Knabb, P C, Wong, M R, Wright, R R, Wexler   +7 more
openaire   +2 more sources

Nonbenzamidine compounds as selective factor xa inhibitors

Bioorganic & Medicinal Chemistry Letters, 2000
Nonbenzamidine compounds (imidazole, pyridine, pyrimidine, and thiazole derivatives) as selective serine protease factor Xa inhibitors are discussed.
W, He, B, Hanney, M R, Myers, A P, Spada, K, Brown, D, Colussi, V, Chu   +6 more
openaire   +2 more sources

Novel factor Xa inhibitors: a patent review

Expert Opinion on Therapeutic Patents, 2009
New oral anticoagulants with favorable safety profiles and fixed doses are required for the management of thromboembolism and stroke prevention in patients with atrial fibrillation. Among them, fXa inhibitors (the so-called xabans) are attractive options that can overcome limitations (e.g., bleeding) of the current oral antithrombotic therapy.
DE CANDIA, MODESTO, ALTOMARE, Cosimo Damiano, LOPOPOLO G   +2 more
openaire   +3 more sources

Fondaparinux, the first selective factor Xa inhibitor

Current Opinion in Hematology, 2003
Fondaparinux (Arixtra, Sanofi-Synthelabo, Paris, France) is a pentasaccharide that selectively inhibits factor Xa; it is the first of a new class of synthetic antithrombotic agents. Fondaparinux has a linear pharmacokinetic profile allowing once-daily subcutaneous administration.
Alexander G G, Turpie, Bengt I, Eriksson, Michael R, Lassen, Kenneth A, Bauer   +3 more
openaire   +2 more sources

Nonbenzamidine tetrazole derivatives as factor Xa inhibitors

Bioorganic & Medicinal Chemistry Letters, 2003
Factor Xa (fXa) is an important serine protease that holds the central position linking the intrinsic and extrinsic activation mechanisms in the blood coagulation cascade. Therefore, inhibition of fXa has potential therapeutic applications in the treatments of both arterial and venous thrombosis.
Mimi L, Quan, Christopher D, Ellis, Ming Y, He, Ann Y, Liauw, Francis J, Woerner, Richard S, Alexander, Robert M, Knabb, Patrick Y S, Lam, Joseph M, Luettgen, Pancras C, Wong, Matthew R, Wright, Ruth R, Wexler   +11 more
openaire   +2 more sources

Factor Xa inhibitors

Expert Opinion on Therapeutic Patents, 1999
F Al-Obeidi, JA Ostrem
openaire   +1 more source